BioSpace News Archive

NRx Pharmaceuticals today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMI™.

Precision BioSciences, Inc. today announced that Michael Amoroso has been named as the Company’s President and Chief Executive Officer and a member of the Precision BioSciences Board of Directors, in each case effective October 15, 2021.

Aviceda is partnering with world-renowned glyco-chemist Prof. Geert-Jan Boons and analytical glyco-biologist Dr. Parastoo Azadi and their teams at Complex Carbohydrate Research Center (CCRC) to spearhead development of the next generation of glyco-immune therapeutics

Crinetics Pharmaceuticals, Inc. today announced newly disclosed program will be presented in a late-breaking poster at the upcoming annual meeting of the American Society for Bone and Mineral Research (ASBMR), which is being held October 1-4, 2021.

Navidea Biopharmaceuticals, Inc. today announced the appointment of Michel Mikhail, Ph.D. as Chief Regulatory Officer of Navidea, effective October 1, 2021.

Aerie Pharmaceuticals, Inc. today announced that the Benjamin F. McGraw, III, Pharm.D., Interim Executive Chairman and David A. Hollander, M.D., M.B.A., Chief R&D Officer, will participate in a fireside discussion at the virtual Cantor Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40 a.m. Eastern Time.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), today announced that four abstracts for Arcutis’ topical roflumilast program in psoriasis, scalp and body psoriasis, and seborrheic dermatitis will be presented at European Academy of Dermatology and Venereology (EADV) Congress.

Nemaura Medical, Inc. announces that it has signed a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”).

New data from Eli Lilly and Company’s (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine therapy, in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) high risk early breast cancer will be presented at the October 14 European Society for Medical Oncology (ESMO) Virtual Plenary.

Aerin Medical Inc., a company dedicated to providing Ear Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced key events at upcoming annual meetings for the American Rhinologic Society (ARS 2021) and American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF 2021).